Australian clinical-stage biotech developing RNA-based therapies (antisense oligonucleotides) for inherited eye diseases and other genetic disorders.
Australian clinical-stage biotech developing RNA-based therapies (antisense oligonucleotides) for inherited eye diseases and other genetic disorders.
Has no approved product, so money comes from raising capital and from Australian R&D tax incentive refunds, with partnership payments a possible later source.
In one line: An early-stage RNA-therapeutics biotech.
Moat: narrow (IP / patents). Proprietary RNA-targeting chemistry and patents on specific genetic targets protect pipeline candidates.
Headquarters: Perth, Australia · Founded: 2013
Size PYC Therapeutics (PYC.AX) is an Australia Health Care company (Pharmaceuticals: Major) with a market value of $1.09B, the 160th largest of 317 Australia companies the cockpit tracks. Shares closed at A$1.74 on 18 Nov 2026.
Performance Over six months the shares gained 29.5%, against -7.1% for the median peer and +1.2% for the Australia market (cap-weighted) — 2nd highest of 20 in its peer set.
Capital Return on invested capital runs 33.0 points below its cost of capital (9.5% WACC).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$0 | A$0 | A$0 | A$0 | A$0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -A$1.20M | -A$1.20M | -A$1.12M | -A$1.07M | -A$882,045 |
| EBITDA | -A$81.5M | -A$81.5M | -A$74.8M | -A$59.4M | -A$38.3M |
| Net income | -A$43.3M | -A$43.3M | -A$50.3M | -A$37.7M | -A$22.8M |
| Free cash flow | -A$45.1M | -A$45.1M | -A$52.5M | -A$38.9M | -A$24.9M |
| Capital expenditure | A$531,391 | A$531,391 | A$975,397 | A$307,044 | A$491,116 |
| Total debt | n/a | A$624,988 | A$1.02M | A$1.11M | A$315,487 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| PYC Therapeutics PYC.AX | $1.09B | +29% | n/a | n/a | n/a | n/a |
| Ionis Pharmaceuticals IONS | $4.56B | -64% | -1% | -59% | 5.0× | n/a |
| ProQR Therapeutics PRQR | n/a | -23% | n/a | n/a | n/a | n/a |
| Wave Life Sciences WVE | $546M | -55% | -35% | -321% | 2.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PYC.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.5% | -1.1% | 8th lowest of 21 |
| 6-month return | +29.5% | -7.1% | 2nd highest of 20 |
| Distance from 52-week high | -40.8% | -25.0% | 4th lowest of 21 |
| ROIC minus cost of capital | -33.0 pp | -0.2 pp | 2nd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | 49.6× | n/a | n/a |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 1.5× | -3.6% | +4.2% |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | 2.4× | 1.0% | -4.2% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 17.3× | n/a | n/a |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 2.3× | 4.9% | +11.3% |
| ST Pharm 237690.KS | South Korea | $1.11B | -51% | +26% | 18% | 3.5× | 4.2% | +21.7% |
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 2.9× | 36.3% | +20.4% |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 1.2× | n/a | n/a |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 8.2× | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 4.2× | 3.4% | -1.2% |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 3.0× | n/a | n/a |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 1.4× | n/a | n/a |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 8.1× | 40.8% | +13.8% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | 1.5× | 2.5% | +6.5% |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 3.2× | -5.6% | +12.7% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 1.7× | -6.5% | -7.7% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 1.2× | -0.3% | +12.1% |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 2.6× | -4.0% | -9.0% |